Company news: Corcept Therapeutics and Daiichi Sankyo

Share this article:

Corcept Therapeutics said Thursday its Cushing's syndrome drug will be launched April 11, three weeks earlier than expected. Korlym (mifepristone) will wholesale at $0.62 per milligram, or $186 per 300-mg tablet, VP of commercial operations Steven Lo told MM&M. The FDA approved the once-a-day treatment in February. It's the first FDA-sanctioned drug for the rare disease. Lo said the company had set an internal goal to have Korlym hit pharmacy shelves soon after April 8, which is Cushing's Awareness Day.

Daiichi Sankyo is starting April with a new global slogan: "Passion for Innovation. Compassion for Patients." It will be the first uniform slogan for the company since the 2006 merger which brought Daiichi Pharmaceutical and Sankyo under one roof. Marah Binder, DSI senior manager for corporate public relations, told MM&M that the slogan is part of a push toward a unified global image, and that the company had been sifting through iterations for more than a year. The new tagline will be slowly rolled out as of the first of the month.

Share this article:

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.